Latest Asx Company Filings News

Capricorn Metals delivered a robust start to FY26 with record quarterly gold production at Karlawinda, while advancing major expansion projects on schedule and within budget.

Great Boulder Resources reports significant high-grade gold intersections at its Side Well South prospect, advancing rapidly towards an initial Mineral Resource Estimate. The latest drilling highlights wide, shallow mineralisation that could boost the project’s overall gold inventory.

Solstice Minerals has confirmed significant high-grade gold mineralisation in fresh rock at its Edjudina Range prospect, marking a promising step forward in the Yarri Gold Project exploration.

Turners Automotive Group has declared a higher Q1 FY26 dividend of 7 cents per share, up from 6 cents last year, reflecting steady financial health and shareholder returns.

Acumentis Group Limited has acquired a significant minority stake in its Mandurah franchisee, Valuations Pty Ltd, aiming to boost earnings and deepen collaboration across Western Australia and nationally.

E79 Gold Mines has executed a binding agreement to acquire a majority stake in the Cue Gold Project, a highly prospective asset in Western Australia's Murchison region, backed by a successful $3 million capital raise to fast-track exploration.

ASIC has initiated civil proceedings against Fiducian’s subsidiary, alleging misleading statements and compliance failures related to a now-closed investment fund. Fiducian is cooperating but remains tight-lipped as the case unfolds.

GoldArc Resources has unveiled strong assay results from its Leonora South drilling program, confirming a robust gold system at Eclipse and Challenge prospects with high-grade, near-surface mineralisation. The company is now targeting a maiden Mineral Resource Estimate and further drilling to expand the resource.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.